Form 4: Guardant Health Co-CEO Reports Insider Stock Transactions

Guardant Health's Co-Chief Executive Officer, AmirAli Talasaz, reported multiple transactions involving common stock and restricted stock units, including vesting and tax-related dispositions.

Summary

• AmirAli Talasaz, Co-Chief Executive Officer and Director of Guardant Health, Inc., reported multiple transactions involving common stock and restricted stock units (RSUs).
• On January 1, 2026, 13,209 shares of common stock were transferred from direct to indirect ownership, held by the Talasaz and Eskandari 2017 Family Trust.
• Also on January 1, 2026, 38,283 restricted stock units (granted March 12, 2025) vested, with 19,402 shares disposed of at $102.14 to cover tax withholding obligations.
• On March 13, 2026, 26,961 performance-based restricted stock units vested, with 13,664 shares disposed of at $85.49 for tax withholding.
• On March 17, 2026, new restricted stock unit awards were granted: 11,268 RSUs vesting quarterly in 2026, and 101,409 RSUs vesting over three years starting January 1, 2027.
• Following these transactions, the indirect beneficial ownership of common stock by the Talasaz and Eskandari 2017 Family Trust was 2,128,489 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, reflecting standard executive compensation activities and compliance with reporting requirements, without indicating significant positive or negative operational news.

Positives

• Vesting of 38,283 restricted stock units on January 1, 2026, and 26,961 performance-based restricted stock units on March 13, 2026, indicates the realization of executive compensation.
• Grant of new restricted stock unit awards totaling 112,677 shares on March 17, 2026, aligns executive incentives with future company performance and retention.

Negatives

• Disposition of 19,402 shares at $102.14 and 13,664 shares at $85.49 to cover tax withholding obligations reduces the direct shareholdings of the executive.

Future Outlook

Future vesting schedules for restricted stock units include quarterly installments over the remaining two-year period after January 1, 2026, for an award granted March 12, 2025. A new RSU award granted March 17, 2026, will vest in four equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. Another RSU award granted March 17, 2026, will vest over a three-year period, with 33% vesting on January 1, 2027, and the remaining 67% in equal quarterly installments over the subsequent two years.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider activity, common across all publicly traded companies, and reflect standard executive compensation practices involving equity awards. The reported transactions, including RSU vesting and tax-related dispositions, are typical for executives receiving equity-based compensation.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Restricted Stock Units (RSUs) and Performance-Based Restricted Stock Units (PBRSUs) for executive compensation is a common practice in the biotechnology and healthcare technology sectors, aligning with compensation structures seen at companies like Illumina (ILMN) or Exact Sciences (EXAS), which often tie executive incentives to long-term performance and retention.
• The tax withholding for vested awards is also a standard industry practice to cover statutory tax obligations upon the vesting of equity awards.

Related Party Transactions

• Transfer of 13,209 shares of common stock from direct ownership to indirect ownership via the Talasaz and Eskandari 2017 Family Trust.

Stakeholder Impact

• Shareholders gain transparency into executive compensation and insider holdings.
• Employees are not directly impacted by these specific executive transactions.
• Customers, suppliers, and creditors are not directly impacted by these insider trading disclosures.

Next Steps

• Continued vesting of restricted stock units granted on March 12, 2025, in equal quarterly installments over the remaining two-year period after January 1, 2026.
• Vesting of 11,268 restricted stock units in four equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
• Vesting of 101,409 restricted stock units, with 33% on January 1, 2027, and the remaining 67% in equal quarterly installments over the subsequent two-year period.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, including the vesting of restricted stock units and subsequent tax-related dispositions, as well as new RSU grants. These activities are standard for executive compensation and do not provide new fundamental information about Guardant Health's operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as the filing itself does not present a catalyst for significant price movement.

Keywords

Guardant Health, GH, AmirAli Talasaz, insider trading, Form 4, stock transactions, restricted stock units, RSU, performance-based restricted stock units, PBRSU, beneficial ownership, executive compensation